Article Text

PDF

Allele *2 of the HS1,2A enhancer of the Ig regulatory region associates with rheumatoid arthritis
  1. B Tolusso1,
  2. D Frezza2,
  3. C Mattioli2,
  4. A L Fedele1,
  5. S Bosello1,
  6. F Faustini1,
  7. G Peluso1,
  8. V Giambra2,
  9. D Pietrapertosa1,
  10. A Morelli1,
  11. E Gremese1,
  12. M De Santis1,
  13. G F Ferraccioli1
  1. 1
    Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
  2. 2
    Department of Biology Enrico Calef, University of Tor Vergata, Rome, Italy
  1. Professor G F Ferraccioli, Division of Rheumatology, School of Medicine, Catholic University of the Sacred Heart, Via Moscati 31, Rome 00168, Italy; gf.ferraccioli{at}rm.unicatt.it

Abstract

Objective: To investigate the role of the HS1,2 enhancer polymorphisms as a new candidate marker for rheumatoid arthritis (RA) and to define the possible association with autoantibody positivity and clinical outcome.

Methods: Genomic DNA was obtained from two cohorts of patients with RA (100 with early RA (ERA) and 114 with longstanding RA (LSRA)) and from 248 gender-matched controls from the same geographical area. Clinical and immunological characteristics were recorded for all the patients.

Results: The percentage of the 2/2 genotype was higher in patients with ERA (27.0%), and in patients with LSRA (34.2%), than in controls (14.9%) (ERA: OR = 2.11 (95% CI 1.20 to 3.70) vs controls; LSRA: OR = 2.96 (95% CI 1.76 to 5.00) vs controls). A lower representation of allele *3 was present in patients with ERA (2.0%) than in controls (6.0%; OR = 0.32 (95% CI 0.11 to 0.91)). No significant associations were found between polymorphisms and autoantibodies positivity.

Conclusion: The HS1,2A allele *2 associates with early and longstanding RA.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

  • Funding: This research was supported by the funding of the Catholic University of Sacred Heart of Rome and University of Tor Vergata, Rome (MIUR PRIN N.20073RH73W_003).

  • Ethics approval: Ethics committee approval obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.